PremiumRatingsNautilus Biotechnology: Hold Rating Amid Delayed Launch and Strategic Adjustments Nautilus Biotechnology’s Earnings Call: Progress Amid Challenges Nautilus Biotechnology price target lowered to $2.50 from $4 at Guggenheim PremiumThe FlyNautilus Biotechnology downgraded to Sell from Neutral at Goldman Sachs Nautilus Biotechnology Faces ESG Challenges Amid Regulatory Pressure and Investor Scrutiny Nautilus Biotechnology Reports Q3 2024 Financial Results PremiumPre-EarningsIs NAUT a Buy, Before Earnings? Nautilus Biotechnology initiated with a Buy at Guggenheim Nautilus Biotechnology initiated with a Buy at Guggenheim